Barcelona-based manufacturer of plasma-derived medicines, Grifols, has appointed Rahul Srinivasan as its new chief financial officer (CFO), effective from Sept. 16, 2024. He will replace Alfredo Arroyo, who is retiring after 17 years with the company.
In his new role, Srinivasan will oversee Grifols' financial functions, including planning, treasury, tax, reporting, investor relations, and sustainability, a company statement said.. He will also implement cash-flow strategies and manage debt plans. Reporting directly to CEO Nacho Abia, Srinivasan will join the executive committee.
Grifols CEO Nacho Abia expressed his excitement about the new appointment. “I am thrilled to welcome Rahul to our team. Rahul’s insights, deep knowledge of corporate finance and broad experience navigating dynamic capital markets, as well as his strong performance-oriented culture, make him an extremely valuable asset for our next chapter of growth.”
Commenting on his appointment, Srinivasan said, “I look forward to partnering with Nacho, his senior management team and the Board of this venerable institution that has made a huge difference to people’s lives with its portfolio of life-changing medicines across a wide range of therapeutic areas.”
Previously, Srinivasan led the EMEA Leveraged Finance and Capital Markets team at Bank of America, achieving significant revenue growth. His 25-year career includes senior roles at KPMG, Credit Suisse, and Bank of America, covering audit, transaction services, corporate finance, mergers and acquisitions, and capital markets.
Srinivasan is a fellow of the Institute of Chartered Accountants in England and Wales (ICAEW) and holds a degree in Business Mathematics and Statistics from the London School of Economics. He also earned an executive MBA from ENPC School of International Management in Paris.
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login